Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs iShares MSCI Singapore ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while iShares MSCI Singapore ETF trades at $34.04. The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | EWS | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $33.92 |
52-Week Low | $16.87 | $26.71 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
EWS, the iShares MSCI Singapore ETF, trades at $33.25, up 2.15% today, with a bullish technical signal from moving averages and oscillators. The ETF offers exposure to Singapore's equity market, highlighted by a 3.97% dividend yield and institutional interest, such as Amundi's 4.8% stake increase in Q2 2026. Recent news emphasizes Singapore's economic resilience and AI-driven growth opportunities.
The outlook for EWS is positive due to Singapore's stable economy and sector reforms, but risks include concentrated holdings in financials and regional volatility. Investors may find value in its diversification benefits and dividend consistency, though monitoring economic shifts in Asia is essential for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
